During the consultation on the draft guidance Janssen, the manufacturer of the drug, submitted further information for the committee to consider.
This included a revised patient access scheme which involves providing the drug to the NHS at a discounted price, further information on which patients would benefit most and clarification on how many patients could receive the drug.
These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS.
More top news
Vacuum cleaner manufacturer Dyson has said that it will invest £2 billion in electric car development.
Victims have won a ruling allowing them to launch a High Court group action seeking damages over contaminated blood products.
Jaffa Cake fans have been left outraged after boxes of the biscuits dropped in size from 12 to 10.